Reversing ageing by targeting mitochondria

MPC Therapeutics SA

Incorporated

09.11.2018

Headquarters

Genève

Support

MPC Therapeutics is a biotech company developing first-in-class small molecules that target the Mitochondrial Pyruvate Carrier (MPC), a key metabolic switch controlling stem cell activation. By restoring regenerative capacity, MPC enhances cell therapy manufacturing and develops novel treatments for diseases such as Alzheimer’s and hair loss, addressing major unmet medical needs.

In January 2026, MPC Therapeutics has launched the commercialization of its first product "MitoSTEM", a reagent designed to boost stem cell proliferation in culture , before transplantation.

Founded as a spin-out from UNIGE, MPC Therapeutics is the first Swiss company to join JLABS, the incubator of Johnson & Johnson, and has won the Best european startup award at HWL Luxembourg.